Lactobacillus plantarum QL01 with antioxidant capacity and application of lactobacillus plantarum QL01
By isolating and identifying Lactobacillus plantarum QL01 with high antioxidant ability, the safety and efficiency of natural antioxidants in the prior art were solved, and the significant antioxidant and anti-inflammatory effects in aging mice were achieved, and functional Food and drug development.
Patent Information
- Application Number
- CN202411407957.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-10
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, chemically synthesized antioxidants have potential harm to the human body, and the antioxidant abilities of lactic acid bacteria of different sources vary greatly, making it difficult to find efficient and safe natural antioxidants.
Isolated and identified a plant Lactobacillus plantarum QL01 with high antioxidant capacity to prepare antioxidant, anti-aging and anti-inflammatory preparations, which can stabilize colonization in the intestine, optimize intestinal flora, and improve the total resistance of aged mice. Oxidase activity, reducing oxidative stress and inflammatory states.
Lactobacillus plantarum QL01 significantly improved the antioxidant enzyme activity of aged mice, reduced liver tissue damage, improved anti-inflammatory factors, significantly alleviated the oxidative stress and inflammation status of aged mice, and has a wide range of functional foods, Application potential of fermented products and pharmaceuticals.
Smart Images

Figure CN118995529A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and in particular relates to a strain of Lactobacillus plantarum QL01 with antioxidant ability and application thereof. Background Art
[0002] Oxidative stress refers to the excessive production of highly active molecules such as reactive oxygen free radicals (ROS) in the body when the body is subjected to various harmful stimuli, resulting in an imbalance between the oxidative system and the antioxidant system, leading to diseases such as tissue damage, inflammatory response, and aging. Oxidative stress in the body is closely related to aging, and aging can be delayed by reducing oxidative damage. Antioxidants can alleviate the harm caused by oxidative stress. At present, people mainly reduce the occurrence of oxidative stress by taking synthetic antioxidants or eating foods containing antioxidants, but chemically synthesized antioxidants are potentially harmful to the human body. Therefore, it is extremely important to find and develop effective, safe and non-toxic natural antioxidants from biological resources.
[0003] Lactic acid bacteria are a type of bacteria that can produce a large amount of lactic acid by fermenting carbohydrates. They have antioxidant and anti-aging functions. They are a natural antioxidant resource with great potential because they are easy to obtain, low-cost, safe and harmless. Although lactic acid bacteria have antioxidant capacity, the antioxidant capacity of strains from different sources varies greatly, so the separation and screening of lactic acid bacteria with high antioxidant capacity has become a research hotspot.
[0004] Yak milk and dairy products are rich in lactic acid bacteria and are a treasure trove of lactic acid bacteria. Due to the relatively harsh environment in which yak milk and dairy products are produced, the lactic acid bacteria in these foods can still survive and reproduce, and their biological properties are optimized, so that the bacterial flora can tolerate oxidative stress. How to isolate a strain from yak milk and dairy products that can be efficiently utilized and has strong anti-oxidative stress ability remains to be studied. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a strain of Lactobacillus plantarum QL01 with antioxidant capacity and application thereof.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The invention provides a strain of Lactobacillus plantarum QL01 with antioxidant ability. The preservation number of the Lactobacillus plantarum QL01 is CCTCC NO: M20241615.
[0008] The present invention provides application of the Lactobacillus plantarum QL01 in preparing an antioxidant preparation.
[0009] Preferably, the application in the preparation of antioxidant preparations includes scavenging free radicals DPPH, ABTS + OH - or 2- .
[0010] The present invention provides application of the Lactobacillus plantarum QL01 in preparing an anti-aging preparation.
[0011] The present invention provides the use of the Lactobacillus plantarum QL01 in the preparation of an anti-inflammatory preparation, wherein the anti-inflammatory effect includes increasing the level of the anti-inflammatory factor IL-10 and reducing the levels of the pro-inflammatory factors TNF-α, IL-1β and IL-6.
[0012] The present invention provides the use of the Lactobacillus plantarum QL01 in preparing a health product for regulating intestinal flora.
[0013] The present invention provides application of the Lactobacillus plantarum QL01 in preparing fermented food.
[0014] The present invention provides application of the Lactobacillus plantarum QL01 in preparing cosmetics or medicines.
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] The plant lactobacillus QL01 provided by the present invention originates from the special geographical and climatic conditions of low temperature, low oxygen, strong ultraviolet and the like in the Tibetan plateau, and can supplement and expand the establishment of a high-quality lactic acid bacteria germplasm resource bank under the extreme environmental conditions in the Tibetan areas in western my country. The plant lactobacillus QL01 of the present invention can be stably colonized in the intestine, optimize the intestinal flora, and also has high antioxidant activity, can effectively improve the organ index of aging mice, reduce the damage of liver tissue of aging mice, and significantly improve the total antioxidant enzyme (T-AOC), glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) activities in the liver of aging mice, and significantly reduce the activity of malondialdehyde (MDA); in addition, the plant lactobacillus QL01 can significantly increase the level of anti-inflammatory factor interleukin-10 (IL-10) in the serum of aging mice, and significantly reduce the levels of pro-inflammatory factors tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), can effectively alleviate the oxidative stress and inflammatory state of aging mice, and can be widely used in functional foods, fermented products, cosmetics and medicines.
[0017] Biological Deposit Description
[0018] The Lactobacillus plantarum QL01 involved in the present invention was deposited in the China Type Culture Collection of Wuhan University, Wuhan, China on July 22, 2024, and its deposit number is CCTCC NO: M 20241615. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 are the growth characteristics of lactic acid bacteria, where A is the 24-hour growth curve of different strains, B is the growth of different strains at different temperatures, and C is the growth of different strains at different salt concentrations;
[0020] Figure 2 is the adhesion of different lactic acid bacteria, where A is the hydrophobicity of different strains, B is the self-aggregation rate of different strains, and C is the copolymerization of different strains;
[0021] Figure 3 Effects of Lactobacillus plantarum QL01 on oxidative damage induced by d-galactose in aged mice, where A is the T-AOC level, B is the MDA level, C is the SOD level, D is the CAT level and E is the GSH level.
[0022] Figure 4 This is a graph showing that Lactobacillus plantarum QL01 improves serum inflammation in aging mice induced by d-galactose, where A is the serum IL-10 content, B is the serum TNF-α content, C is the serum IL-1β content, and D is the serum IL-6 content. DETAILED DESCRIPTION
[0023] The present invention provides a strain of Lactobacillus plantarum QL01 with antioxidant ability. The Lactobacillus plantarum QL01 has a preservation number of CCTCC NO: M20241615 and is deposited in the China Type Culture Collection of Wuhan University, Wuhan, China on July 22, 2024, with a preservation number of CCTCC NO: M 20241615.
[0024] The present invention provides application of the Lactobacillus plantarum QL01 in preparing an antioxidant preparation.
[0025] In the present invention, the application in the preparation of antioxidant preparations includes scavenging free radicals DPPH, ABTS + OH - or 2- .
[0026] The present invention provides application of the Lactobacillus plantarum QL01 in preparing an anti-aging preparation.
[0027] In the present invention, the application in the preparation of anti-aging preparations is achieved by increasing the activities of total antioxidant enzymes (T-AOC), glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) in the liver, and significantly reducing the activity of malondialdehyde (MDA).
[0028] The present invention provides the use of the Lactobacillus plantarum QL01 in the preparation of an anti-inflammatory preparation, wherein the anti-inflammatory effect includes increasing the level of the anti-inflammatory factor IL-10 and reducing the levels of the pro-inflammatory factors TNF-α, IL-1β and IL-6.
[0029] The present invention provides the use of the Lactobacillus plantarum QL01 in preparing a health product for regulating intestinal flora.
[0030] In the present invention, the intestinal flora is regulated by utilizing the strong intestinal colonization ability and gastrointestinal tolerance of Lactobacillus plantarum QL01 to optimize the intestinal flora.
[0031] The present invention provides the use of the Lactobacillus plantarum QL01 in the preparation of fermented food, and the fermented food is preferably fermented milk.
[0032] The present invention provides application of the Lactobacillus plantarum QL01 in preparing cosmetics or medicines.
[0033] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0034] Example 1 Isolation, purification and identification of lactic acid bacteria
[0035] 1. Sample Source
[0036] Food samples were collected from different eco-geographical regions and yak distribution areas in Gansu and Qinghai provinces, including yak milk, yogurt, cheese, curd, ghee and qula.
[0037] 2. Isolation and purification of lactic acid bacteria
[0038] Take 1mL / 1g of food sample and dilute it with sterile saline in a gradient ratio of 1:10, then take 10 -4 , 10 -5 , 10 -6 , 10 -7 200 μL of the dilutions of the concentration gradient were spread on MRS solid medium, and each concentration was repeated 3 times, and cultured at 37°C for 36 hours. Single colonies with different colony sizes and morphologies were selected, and streaked for 3 generations to obtain purified strains.
[0039] 3. Identification and preservation of lactic acid bacteria
[0040] The purified single strains were identified using the fully automatic rapid microbial mass spectrometry detection and data management system (MALDI Biotyper sirius). As a result, more than 1,200 single strains were identified, including Lactobacillus plantarum, Lactococcus lactis, Enterococcus faecalis, Leuconostoc mesenteroides, Streptococcus salivarius subsp.thermophilus and other genera. These strains were added with 50% glycerol and stored in a -80°C ultra-low temperature refrigerator.
[0041] Example 2: Screening of antioxidant lactic acid bacteria
[0042] 1. Initial screening
[0043] (1) Determination of DPPH free radical scavenging ability
[0044] The lactic acid bacteria fermentation liquid activated to the logarithmic phase was adjusted to a concentration of 1×10 8 CFU / mL. Mix 1mL of sample with 1mL of 0.2mmol / L DPPH anhydrous ethanol solution, shake and mix, react at room temperature in the dark for 30min, centrifuge at 4℃ and 4000r / min for 10min, take the supernatant and measure the OD value at 517nm. Anhydrous ethanol replaces DPPH as blank, and sterile water replaces sample as control.
[0045] DPPH free radical scavenging rate (%) = [1-(Ai-Aj) / A0] × 100
[0046] Wherein: Ai is the absorbance of sample + DPPH; Aj is the absorbance of sample + anhydrous ethanol; A0 is the absorbance of sterile water + DPPH.
[0047] In the experiment, 127 strains of lactic acid bacteria with strong DPPH scavenging ability were screened out.
[0048] (2) Determination of H2O2 tolerance
[0049] The lactic acid bacteria fermentation broth with strong DPPH scavenging ability in the above (1) was inoculated at an inoculation rate of 3% into MRS liquid culture medium with initial H2O2 concentrations of 0, 1, 2, and 3 mmol / L, cultured at 37°C for 24 h, and the OD600 nm values at different H2O2 concentrations were measured.
[0050] In the experiment, 26 strains of lactic acid bacteria with strong H2O2 tolerance were screened out.
[0051] Second, re-screening
[0052] All 26 lactic acid bacteria with strong DPPH scavenging ability and H2O2 tolerance in the initial screening were used for rescreening.
[0053] (1) Preparation of cell-free fermentation supernatant (CFS), intact cells (IC) and cell-free extracts (CFE) of strains
[0054] The strains were streaked on MRS solid medium and cultured at 37°C for 48 h. A single colony was picked and inoculated into sterile MRS liquid medium and cultured at 37°C for 24 h to obtain a culture solution. The culture solution was adjusted to a bacterial cell concentration of 10 9 CFU / mL, centrifuged at 4°C and 10000r / min for 15min, collected the supernatant, and filtered with a 0.22μm microporous filter membrane to obtain the cell-free fermentation supernatant.
[0055] Resuspend the centrifuged bacterial pellet in sterile PBS (pH = 7.4) and centrifuge at 4°C, 10,000 r / min for 15 min, repeat 3 times. Resuspend the washed bacterial pellet in PBS and adjust the bacterial concentration to 10 9 CFU / mL, and the bacterial suspension was obtained.
[0056] The bacterial suspension was taken for ultrasonic cell disruption in an ice bath (amplifier Φ6, ultrasound on 5s, off 5s, power 300W, 30min), and the supernatant was taken after disruption by centrifugation to obtain a cell-free extract.
[0057] (2) Determination of DPPH free radical scavenging ability
[0058] The specific method is the same as the primary screening.
[0059] (3)ABTS + Free radical scavenging ability
[0060] Mix 7mmol / L ABTS solution and 2.45mmol / L potassium peroxide solution in a ratio of 1:1 (V:V), and react at room temperature in the dark for 12-16h to prepare ABTS mother solution. Take an appropriate amount of ABTS mother solution and dilute it with 95% anhydrous ethanol to an absorbance of 0.70±0.02 to prepare ABTS working solution. Add 0.6mL of sample and 2.4mL of ABTS working solution to a test tube, let stand for 6min at room temperature in the dark, and measure absorbance at 734nm.
[0061] ABTS free radical scavenging rate (%) = [(A0-As) / A0] × 100
[0062] Where: As is the absorbance of the sample; A0 is the absorbance of the sample replaced by sterile water.
[0063] (4) OH-free radical scavenging ability
[0064] Add 2mL of the sample to be tested, 2mL of 9mmol / LFeSO4, 2mL of 9mmol / L salicylic acid solution and 2mL of 8.8mmol / L H2O2 solution into the test tube, mix thoroughly, place in a 37℃ water bath for 30min, and measure the OD value at 510nm. Use sterile water instead of H2O2 as blank and sterile water instead of sample as control.
[0065] OH - Free radical scavenging rate (%) = [A0-(Ai-Aj) / A0] × 100
[0066] Where: Ai is the absorbance of the sample; Aj is the absorbance of sterile water instead of H2O2; A0 is the absorbance of sterile water instead of the sample.
[0067] (5)O 2- Free radical scavenging ability
[0068] Add 0.1 mL of the sample to be tested, 2.8 mL of Tris-HCl buffer solution (0.05 mol / L, pH=8.2) and 0.1 mL of pyrogallol (0.05 mol / L) into a test tube, shake it evenly, and place it in a water bath at 25°C in the dark for 4 min. After the reaction is completed, add 1 mL of HCl (8 mol / L) to terminate the reaction, and measure the absorbance at 320 nm.
[0069] O 2- Free radical scavenging ability (%) = [A0-(A1-A2)] / A0×100
[0070] Wherein: A0 represents the absorbance of the sample replaced by sterile water; A1 represents the absorbance of the sample; A2 represents the absorbance of pyrogallol replaced by sterile water.
[0071] (6) Total reducing power
[0072] Add 0.5mL of sample, 0.5mL of potassium ferricyanide (mass fraction 1%), and 0.5mL of sterile phosphate buffer solution (0.2M, pH = 6.6) to a centrifuge tube, and shake thoroughly to mix. Place in a 50℃ water bath for 20min, cool, add 0.5mL of trichloroacetic acid (mass fraction 10%), centrifuge at 4℃, 4500r / min for 10min, take 1mL of supernatant, add 1mL of FeCl3 (mass fraction 0.1%) and 1mL of sterile water, vortex to mix, let stand at room temperature for 10min, and measure the OD value at a wavelength of 700nm. Use sterile saline instead of the sample as a blank group, and use the difference in OD values between the blank group and the experimental group to characterize the strength of the reducing ability.
[0073] Reduction power = A1-A0
[0074] Where: A1 is the absorbance value of the sample; A0 is the absorbance value of 0.5 mL of sterile saline instead of the sample.
[0075] (7) Select strains with strong comprehensive antioxidant capacity
[0076] Combining the results of various antioxidant indexes of different components of lactic acid bacteria in the rescreening (see Tables 1, 2, 3, 4, and 5), 9 strains with strong comprehensive antioxidant capacity were selected, namely, Enterococcus faecalis TDc2-4, XHm3-3, XHm4-1, HZy3-1, Lactobacillus plantarum QL01, Pediococcus pentosaceus ZNc1-5, Lactobacillus brevisfermentans MQUm2-1, Enterococcus durileus TZc1-2, and Leuconostoc lactis XHm4-2.
[0077] Table 1 DPPH free radical scavenging rate of 9 bacterial strains
[0078]
[0079] Table 2 ABTS of 9 bacterial strains + Free radical scavenging rate
[0080]
[0081]
[0082] Table 3 OH of 9 bacterial strains - Free radical scavenging rate
[0083]
[0084] Table 4 O of 9 strains 2- Free radical scavenging rate
[0085]
[0086]
[0087] Table 5 Total reducing power of 9 bacterial strains
[0088]
[0089] Note: All data are expressed as mean ± standard deviation (n = 3), and “-” indicates no clearance ability.
[0090] Example 3: In vitro probiotic properties study
[0091] All nine strains of lactic acid bacteria with strong antioxidant activity were used for the study of their probiotic properties.
[0092] (1) Safety evaluation
[0093] ①Hemolytic activity
[0094] The lactic acid bacteria activated to the logarithmic phase were streaked on Columbia blood agar plates and incubated at 37°C for 48 hours to observe whether there was a hemolytic ring around the colonies. Staphylococcus aureus was used as a positive control.
[0095] Table 6 Hemolytic activity of 9 lactic acid bacteria strains
[0096]
[0097]
[0098] Note: α: α hemolytic; β: β hemolytic; γ: γ hemolytic
[0099] ② Antibiotic sensitivity
[0100] Take 0.1mL of the bacterial suspension of the strain to be tested (the bacterial concentration is adjusted to 10 8 CFU / mL) was spread on MRS solid culture medium, and sterile tweezers were used to place drug-sensitive paper discs of ampicillin, penicillin, chloramphenicol, tetracycline, penicillin, gentamycin, ciprofloxacin, erythromycin, ceftriaxone, cotrimoxazole and lincomycin on the surface of the culture medium, and the drug-sensitive discs were gently pressed to make them stick firmly. After culturing at 37°C for 24-48h, the diameter of the inhibition zone of the drug-sensitive discs was measured.
[0101] Table 7 Antibiotic sensitivity of 9 lactic acid bacteria strains
[0102]
[0103]
[0104] Note: R stands for drug resistance; I stands for intermediate sensitivity; S stands for sensitive.
[0105] The results show that: Based on the results of Table 6 and Table 7, except for Lactobacillus lactis XHm4-2 and Enterococcus durileus TZc1-2, the other 7 strains were γ-hemolytic, which proved to be safe and sensitive to most antibiotics. Therefore, the 7 safe strains were selected for subsequent experiments.
[0106] (2) Growth characteristics
[0107] ① Growth curve
[0108] The lactic acid bacteria activated to the logarithmic phase were inoculated into sterile MRS liquid culture medium at a ratio of 3%, and cultured at 37°C for 24 hours. The OD600 nm value of the culture medium was measured every 2 hours. The sterile MRS liquid culture medium without bacterial liquid inoculation was used as a control to draw a growth curve.
[0109] ②Effects of different temperatures on the growth of lactic acid bacteria
[0110] The lactic acid bacteria activated to the logarithmic phase were inoculated into sterile MRS liquid culture medium at a ratio of 3%, and cultured at 4°C, 25°C, 37°C, and 45°C for 24 hours, respectively. The sterile MRS liquid culture medium without inoculation of bacterial liquid was used as a control.
[0111] ③Effects of different salt concentrations on the growth of lactic acid bacteria
[0112] The lactic acid bacteria activated to the logarithmic phase were inoculated at a ratio of 3% into culture media containing 3.0, 5.0, 8.0 and 10 g NaCl per 100 g MRS broth, respectively, and cultured at 37° C. for 24 h. MRS liquid culture medium without additional NaCl was used as a control.
[0113] The results showed that Lactobacillus plantarum QL01, Pediococcus pentosaceus ZNc1-5 and Lactobacillus brevefermentans MQUm2-1 had excellent growth performance and grew well at different temperatures and salt concentrations, especially Lactobacillus plantarum QL01 had the best growth characteristics (see Figure 1 , Figure 1 A is the 24 h growth curve of different strains, B is the growth of different strains at different temperatures, and C is the growth of different strains at different salt concentrations). Therefore, these three strains were selected for subsequent experiments.
[0114] (3) Adhesion
[0115] The lactic acid bacteria and pathogenic bacteria (Escherichia coli, Salmonella and Staphylococcus aureus) activated to the logarithmic phase were centrifuged at 4°C and 10,000 r / min for 15 min, washed three times with sterile PBS, and resuspended in PBS. The OD600 nm value of the bacterial suspension was adjusted to about 0.5±0.05, which was recorded as A0.
[0116] ①Hydrophobicity
[0117] Take 2 mL of the bacterial suspension with adjusted concentration, add the same volume of xylene, chloroform and ethyl acetate, vortex mix for 5 minutes, let stand at room temperature for 1 hour, take the lower aqueous phase to measure OD600 nm, and record it as At.
[0118] Hydrophobicity (%) = (1-At / A0) × 100
[0119] Where: At represents the OD600 nm value after standing for 1 hour; A0 represents the OD600 nm value of the adjusted bacterial suspension.
[0120] ②Self-aggregation
[0121] Take 5 mL of the bacterial suspension with adjusted concentration and place it in a test tube, vortex mix it, incubate it at 37°C, and measure the OD600 nm value of the upper solution after 0, 2, 4, 6, and 24 hours.
[0122] Self-aggregation rate (%) = (1-At / A0) × 100
[0123] Where: At represents the OD600 nm value after standing for 2, 4, 6, and 24 hours; A0 represents the OD600 nm value at 0 hour.
[0124] ③ Coaggregation
[0125] 2 ml of the bacterial suspension with adjusted concentration was mixed with each pathogen suspension in equal volumes, vortexed for 30 seconds, and then incubated for 5 hours at 37° C. The absorbance of the supernatant of each mixed suspension was measured at 600 nm.
[0126] Coagulation (%) = [1-As / (A0+A1) / 2] × 100
[0127] Where: A0 and A1 are the initial OD600 of lactic acid bacteria and pathogenic bacteria, and As is the initial OD600 of the mixed suspension after incubation for 4 h.
[0128] The results showed that Lactobacillus plantarum QL01 had the best hydrophobicity to xylene, chloroform and ethyl acetate, the highest self-aggregation rate at 2, 4, 6 and 24 hours, and the strongest co-aggregation ability with Escherichia coli, Salmonella and Staphylococcus aureus, indicating that Lactobacillus plantarum QL01 has good adhesion ability and can be well colonized and adhered to the intestine to play a probiotic role (see Figure 2 , Figure 2 A is the hydrophobicity of different strains, B is the self-aggregation rate of different strains, and C is the copolymerization rate of different strains).
[0129] (4) Survival under gastrointestinal conditions
[0130] ① Acid and bile salt tolerance
[0131] The activated lactic acid bacteria were inoculated into MRS liquid medium with pH=3.0 at an inoculum volume of 3%, and cultured at 37°C for 3 hours. Samples were taken at 0 hour and 3 hours of culture, and the absorbance values were measured at a wavelength of 600 nm, and the survival rate was calculated.
[0132] The activated lactic acid bacteria were inoculated at 3% inoculation into MRS liquid medium containing 0.3% ox bile salt or without ox bile salt, and cultured at 37°C for 24 hours. Samples were taken at 0 hours, 3 hours and 24 hours of culture, and the absorbance values were measured at a wavelength of 600 nm, and the survival rate was calculated.
[0133] 3h survival rate (%) = 3h OD600 nm value / 0h OD600 nm value × 100
[0134] 24h survival rate (%) = 24h OD600 nm value / 0h OD600 nm value × 100
[0135] ② Gastrointestinal fluid tolerance
[0136] Simulated gastric fluid: add 0.3g pepsin to 100mL 0.5% sterile saline, shake well and adjust pH to 3.0; simulated intestinal fluid: take 0.1g trypsin and 0.3g bile salt and dissolve them in 100mL 0.2% sterile saline, adjust pH to 6.8. Sterilize the prepared simulated gastrointestinal digestive fluid with a 0.22μm filter membrane for later use.
[0137] Take 1mL of bacterial suspension (adjust the bacterial concentration to 10 9 CFU / mL) and 9mL simulated gastric fluid were mixed and cultured anaerobically in a 37℃ constant temperature shaking incubator for 3h. Samples were taken at 0 and 3h for plate counting. 1mL of the bacterial solution cultured in simulated gastric fluid for 3h was inoculated into 9mL of simulated intestinal fluid, cultured anaerobically in a 37℃ constant temperature shaking incubator for 8h, and samples were taken for plate counting. After all the coated plates were cultured at 37℃ for 48h, plates with colony counts between 30-300 were selected for colony counting.
[0138] Strain survival rate (%) = lgN1 / lgN2×100
[0139] Where: N1 is the colony count after gastrointestinal simulation, CFU / mL; N2 is the colony count before gastrointestinal simulation, CFU / mL.
[0140] The results showed that: as shown in Table 8, the survival rate of Lactobacillus plantarum QL01 was high at pH = 3 and 0.3% bile salt, and the survival rate was as high as 97.47% under simulated gastric fluid for 3 hours, and the survival rate was as high as 81.42% under simulated intestinal fluid for 8 hours, indicating that the strain has good acid and bile salt tolerance, and after digestion by gastric and intestinal juices, it still maintains a high survival rate, plays a role in intestinal colonization, and meets the basic conditions for being a probiotic.
[0141] Table 8 Tolerance of lactic acid bacteria to pH, bile salts and simulated gastrointestinal fluid
[0142]
[0143] Example 4: Animal model experiment
[0144] Fifty SPF male Kunming mice (20±2g) were fed in separate cages and allowed to eat and drink freely. After one week of adaptive feeding, they were randomly divided into five groups (n=10), namely, normal control group (NC), aging model group (MC), positive control group (VC), low-dose bacteria group (LP) and high-dose bacteria group (HP). Each treatment group was fed with a basic diet. The experimental period was 8 weeks. The number of viable bacteria in the low-dose bacteria group was 10 9 CFU / ml and the number of viable bacteria per day in the low-dose group was 10 10 CFU / ml, the positive control group was gavaged with vitamin C (200 mg / kg) daily, and the normal control group and the aging model group were gavaged with the same amount of sterile saline daily. The aging model group, the positive control group and the lactic acid bacteria treatment group were intraperitoneally injected with d-galactose (125 mg / kg) daily, and the normal control group was injected with the same amount of saline daily, with the gavage volume and intraperitoneal injection volume of 200 μL.
[0145] After the last gavage and injection, stop eating for 12 hours, and do not restrict drinking water. Weigh, anesthetize, collect blood from the eyeball, place at 4℃ overnight, centrifuge (3000g, 10min) to separate serum, and store at -80℃ for later use. After blood collection, the animals were killed by vertebral dislocation, and the liver, brain, kidney, thymus, and lung tissues were separated. The surface blood stains were rinsed with pre-cooled saline, wiped dry with medical gauze, and weighed. The liver tissue was stored at -80℃ for testing.
[0146] (1) Determination of organ index
[0147] The organ index of mice was calculated according to the following formula:
[0148] Organ index (%) = organ weight (g) / body weight (g) × 100
[0149] The specific test results are shown in Table 9.
[0150] Table 9 Effects of Lactobacillus plantarum QL01 on organ indexes of d-galactose aged mice
[0151]
[0152]
[0153] Note: Data are expressed as mean ± standard deviation. NC: normal group, MC: model group, VC: positive control group, LP: low-dose group, HP: high-dose group. Compared with MC, * represents P < 0.05; ** represents P < 0.01.
[0154] The results showed that the organ index of aging mice was improved through the intervention of Lactobacillus plantarum QL01.
[0155] (2) Determination of antioxidant enzymes T-AOC, GSH, SOD, CAT activities and malondialdehyde content in liver tissue
[0156] All the specific methods of the indicators were carried out according to the instructions of Nanjing Jiancheng Test Kit. The results are detailed in Figure 3 , Figure 3 A is T-AOC level, B is MDA level, C is SOD level, D is CAT level and E is GSH level. NC: normal group, MC: model group, VC: positive control group, LP: low-dose group, HP: high-dose group, data are expressed as mean ± standard deviation (n = 6), (ad) Means with different letters in the same bar graph are statistically significant (P < 0.05).
[0157] Figure 3 It showed that the intervention of Lactobacillus plantarum QL01 significantly increased the activities of antioxidant enzymes T-AOC, GSH, SOD, and CAT in the liver of aging mice, and significantly reduced the activity of malondialdehyde (MDA).
[0158] (3) Determination of serum levels of inflammatory factors IL-10, TNF-α, IL-1β, and IL-6
[0159] All indicators were tested according to the ELISA kit instructions. Figure 4 , Figure 4 A is the content of IL-10 in serum, B is the content of TNF-α in serum, C is the content of IL-1β in serum, and D is the content of IL-6 in serum.
[0160] Figure 4 The results showed that the intervention of Lactobacillus plantarum QL01 significantly increased the level of anti-inflammatory factor IL-10 in serum, and significantly reduced the levels of pro-inflammatory factors TNF-α, IL-1β, and IL-6. This indicates that Lactobacillus plantarum QL01 alleviates the oxidative stress and inflammatory state of aging mice and has a prebiotic effect in vivo.
[0161] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A strain of Lactobacillus plantarum QL01 having antioxidant capacity, characterized in that: The deposit number of the Lactobacillus plantarum QL01 is CCTCC NO: M 20241615.
2. Use of Lactobacillus plantarum QL01 according to claim 1 in the preparation of antioxidant preparations.
3. The use according to claim 2, characterized in that: The application of the invention in the preparation of antioxidant preparations includes scavenging free radicals DPPH, ABTS + OH - or 2- .
4. Use of Lactobacillus plantarum QL01 according to claim 1 in the preparation of anti-aging preparations.
5. The use of Lactobacillus plantarum QL01 according to claim 1 in the preparation of an anti-inflammatory preparation, characterized in that: The anti-inflammatory effect includes increasing the level of the anti-inflammatory factor IL-10 and decreasing the levels of the pro-inflammatory factors TNF-α, IL-1β and IL-6.
6. Use of Lactobacillus plantarum QL01 according to claim 1 in the preparation of a health product for regulating intestinal flora.
7. Use of Lactobacillus plantarum QL01 according to claim 1 in preparing fermented food.
8. Use of the Lactobacillus plantarum QL01 according to claim 1 in the preparation of cosmetics or medicines.
Citation Information
Patent Citations
Lactobacillus plantarum strain BX62 with antioxidant ability and application thereof
CN109234189A
Application of lactobacillus plantarum strain WKA86 in preparation of medicines for protecting liver, resisting oxidation and preventing and treating alcoholic liver injury
CN114668783A
Lactobacillus reuteri strain A21041 with anti-inflammatory and anti-oxidation functions and application of lactobacillus reuteri strain A21041
CN115948292A
Cited By
Lactobacillus plantarum XZFMCC101.23155, probiotic agent and application of lactobacillus plantarum XZFMCC101.23155
CN120485044A
